July 21st 2023.
Hormosan Pharma GmbH, Lupin's wholly-owned subsidiary in Germany, recently announced the launch of Luforbec 100/6, a fixed combination in a pressurized metered dose inhaler (pMDI) to treat adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Luforbec 100µg/6µg is indicated for adult asthma and COPD treatment where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable. It has the same active ingredients as Foster 100/6 pMDI and an extra fine formulation, offering the same licensed indications and similar device characteristics. Luforbec pMDI offers significant cost savings, priced at 47% below the fixed reference price on the pharmacy selling price.
With a significant portion of the population currently undergoing asthma treatment, Luforbec 100/6 pMDI provides comprehensive support to patients and healthcare professionals. This launch reflects Lupin's commitment to addressing the critical needs of asthma management in Germany.
Anjan Selz, Managing Director of Hormosan Pharma GmbH, commented, "The launch of Luforbec 100/6 pMDI in Germany is a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are dedicated to improving healthcare outcomes by making reliable and comprehensive solutions accessible and affordable to patients and healthcare professionals. This launch reinforces our commitment to making asthma and COPD management more accessible for the German population."
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
